CYCLACEL PHARMACEUTICALS INC (CYCC)       0.7302  -0.04 (-5.17%)

0.7302  -0.04 (-5.17%)

US23254L6039 - Common Stock - After market: 0.736 +0.01 (+0.79%)


Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CYCC. CYCC was compared to 635 industry peers in the Biotechnology industry. Both the profitability and financial health of CYCC have multiple concerns. CYCC has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating

0

The profitability ratios for CYCC are negative, so there is not much use analyzing them.
CYCC's Return On Assets of -61.48% is worse than the rest of the industry. The industry average Return On Assets is -44.83%.

The Piotroski-F score of CYCC is 2.00. This is a very weak score and indicates problems in health and profitability for CYCC.
VS Industry

ROA (-61.48%) VS Industry: 32% outperformed.

-3,944.82
115.38

Valuation

Valuation Rating

3

With a price book ratio of 0.34, CYCC is valued rather cheaply.
When comparing the price book ratio of CYCC to the average industry price book ratio of 1.69, CYCC is valued rather cheaply. CYCC is also cheaper than 92% of the companies listed in the same industry.
Compared to an average industry Enterprise Value to EBITDA ratio of 1.08, CYCC is valued rather cheaply

The Price/Earnings Ratio is negative for CYCC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYCC. No positive earnings are expected for the next year.
VS Industry

Price/Book (0.34) VS Industry: 92% outperformed.

140.12
0.10

Enterprise Value/ EBITDA (0.51) VS Industry: 69% outperformed.

3,199.01
0.01

Growth

Growth Rating

3

CYCC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.41%, which is quite impressive.

CYCC is expected to show a small growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 2.35% yearly.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 37.41% 2.45% -10.82% -12.16% 2.35%
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating

3

A Current Ratio of 6.41 indicates that CYCC has no problem at all paying its short term obligations.
CYCC has a Quick Ratio of 6.41. This indicates that CYCC is financially healthy and has no problem in meeting its short term obligations.
The Current Ratio is in line with the industry averages, which is at 6.11.
CYCC has a Quick Ratio comparable to the industry average, which is at 6.02.

The Debt to Equity ratio of CYCC is in line with the industry averages.
Based on the Altman-Z score of -18.31, we must say that CYCC is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of CYCC to the average industry Altman-Z score of -0.65, CYCC is less financially healthy than its industry peers. 92% of its industry peers have a better Altman-Z score.
CYCC has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for CYCC.
VS Industry

Debt/Equity (0) VS Industry: 41% outperformed.

15.37
0.00

Quick Ratio (6.41) VS Industry: 52% outperformed.

0.02
84.53

Current Ratio (6.41) VS Industry: 52% outperformed.

0.02
85.09

Altman-Z (-18.31) VS Industry: 8% outperformed.

-1,822.12
441.73

Dividend

Dividend Rating

0

No dividends for CYCC!.

CYCC Daily chart

CYCLACEL PHARMACEUTICALS INC0.7302

NASDAQ:CYCC (12/6/2022, 7:00:01 PM)-0.04 (-5.17%)

After market: 0.736 +0.01 (+0.79%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-09 2022-11-09/amc Earnings (Next) 03-27 2023-03-27
Ins Owners 1.16% Inst Owners 18.77%
Market Cap 9.16M Analysts 86
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 0.34
EV/EBITDA 0.51
Dividend
Dividend Yield N/A Dividend Growth N/A
DP -1.05% Ex-Date N/A
Growth
EPS 1Y 37.41% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 22.22%
EPS Next Y 2.45% EPS Next 2Y -10.82%
EPS Next 3Y -12.16% EPS Next 5Y 2.35%
Revenue growth 1Y N/A Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
Health
Current Ratio 6.41 Quick Ratio 6.41
Altman-Z -18.31 F-Score 2
Debt/Equity 0 WACC N/A
ROIC/WACC N/A
Profitability
ROA -61.48% ROE N/A
ROICexgc N/A ROIC N/A
PM N/A OM N/A
Asset Turnover N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA